A clinical trial showed that using an advanced form of TLR3 agonist (Poly-ICLC) promotes cancer cell death and inhibits metastasis by activating several cancer suppressors and rebuilding an immunosuppressive tumor microenvironment [38]. Here, TLR3 is linked to neoplasm.